Montelukast Sodium NDC 57237-212

NDC codes

FDA NDC Directory

Product NDC (as listed)57237-212Labeler and product segments. Claims need a package NDC.

Product NDC at billing width57237-0212Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
57237-212-30	57237021230	30 TABLET, CHEWABLE in 1 BOTTLE (57237-212-30)Marketed from Aug 3, 2012
57237-212-90	57237021290	90 TABLET, CHEWABLE in 1 BOTTLE (57237-212-90)Marketed from Aug 3, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Montelukast Sodium
Generic name (nonproprietary): montelukast sodium
Active ingredients: Montelukast sodium — 4 mg/1
Dosage form: Tablet, Chewable
Route: Oral
Labeler: Rising Pharma Holdings, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202096
Marketing start: Aug 3, 2012
Listing expires: Dec 31, 2027
Other FDA classes: Leukotriene Receptor Antagonists (Mechanism)
Identifiers: Product ID 57237-212_b17c2611-11a0-4762-a99d-3552a93b79cdSPL ID b17c2611-11a0-4762-a99d-3552a93b79cdSPL set ID 49669ac0-0bb5-4576-bed5-9e85e0d76a44RxCUI 200224, 242438, 311759UNII U1O3J18SFL
Pharmacologic class: Leukotriene Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N457237021230 followed by a unit qualifier and the quantity

Package 57237-0212-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Montelukast sodium is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: Not indicated to treat an acute asthma attack ( 5.2 ). 1.1 Asthma Montelukast sodium is indicated for the proph…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202096

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202096
Product	Strength	Form · route	Labeler	Product NDC
Montelukast Sodium	Montelukast sodium 5 mg/1	Tablet, ChewableOral	Aurobindo Pharma Limited	65862-568
Montelukast Sodium	Montelukast sodium 4 mg/1	Tablet, ChewableOral	Aurobindo Pharma Limited	65862-567
Montelukast Sodium	Montelukast sodium 5 mg/1	Tablet, ChewableOral	Rising Pharma Holdings, Inc.	57237-213